Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
vudalimab · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| vudalimab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| vudalimab | BIOLOGICAL | Monoclonal bispecific antibody |
Inclusion Criteria: * Able to provide written informed consent * Adult (age ≥ 18 years) * Cancer must have progressed after treatment with standard of care therapy approved for the treatment of that indication * Histologically confirmed diagnosis of one of the following tumor types, along with clin...
Top 20 of 58 competitors
Vudalimab is an investigational monoclonal antibody being studied for the treatment of ovarian cancer and metastatic castration-resistant prostate cancer. It is also being evaluated in other advanced gynecologic and genitourinary malignancies, including clear cell carcinoma, endometrial cancer, and cervical carcinoma.
Vudalimab is being developed by Xencor, Inc., a biopharmaceutical company. Xencor is conducting clinical trials to evaluate the safety and efficacy of vudalimab in patients with certain advanced cancers.
Vudalimab is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials are ongoing to assess its potential as a treatment for ovarian cancer and metastatic castration-resistant prostate cancer.
Vudalimab is being studied in two Phase 2 clinical trials. NCT05005728 evaluates vudalimab alone or with chemotherapy or targeted therapy in patients with metastatic castration-resistant prostate cancer. NCT05032040 studies vudalimab in patients with advanced gynecologic and genitourinary malignancies, including ovarian cancer.
Vudalimab is a monoclonal antibody, a type of -mab therapeutic. As an antibody, it is designed to bind to specific targets involved in cancer. However, the specific molecular target of vudalimab has not been disclosed in the available information.